Finally, ELISA experiments showed that co-treatment S3I-201 with 0.4 umol/L decitabine reduced IFN-γ release significantly (Figure 5F), whereas pretreatment with the U0126 did not affect IFN-γ release of AML-NK cells. Here, IFNG is linked to acute myeloid leukemia.